At MaaT Pharma, we develop innovative microbiome therapies designed to modulate the immune system and improve outcomes for patients with severe oncology diseases.
Our pipeline spans both hematology and immuno-oncology. MaaT013 (Xervyteg®) is being developed for gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD) following hematopoietic stem cell transplantation and is currently under regulatory review in Europe. We are also advancing next-generation co-cultured microbiome therapies for solid tumors, which are designed to restore immune balance and help strengthen anti-tumor responses in combination with immune checkpoint inhibitors.
Across our pipeline, we wanted to deepen the mechanistic understanding of our microbiome ecosystem therapies. For MaaT013 (Xervyteg®), the objective was to better characterize its immunoregulatory activity in GI-aGvHD. For our MaaT03X candidates, the goal was to evaluate their ability to activate immune cells and drive stronger effector-cell anti-tumor responses, with or without immune checkpoint inhibitors.
For our MaaT03X program, Explicyte designed a stepwise experimental strategy that first assessed activity in PBMCs, B cells, and T cells, and then evaluated each candidate’s ability to enhance the anti-tumor activity of effector cells. Their team also conducted ex vivo analyses on samples generated from animal studies. In parallel, for our MaaT013 (Xervyteg®) program, Explicyte performed in-depth ex vivo analyses to help characterize its mechanism of action in a biologically relevant setting.
These studies helped move our preclinical programs forward, supported by structured, decision-ready reports. Explicyte demonstrated strong expertise across both immunostimulatory and immunoregulatory pathways, while their regular, transparent communication helped facilitate project follow-up and decision-making.
